BiotechTube
Home/Pipeline/Cannabinoid-based Therapy

Cannabinoid-based Therapy

Parkinson's Disease

PreclinicalPartnered for First-in-Human Trial

Key Facts

Indication
Parkinson's Disease
Phase
Preclinical
Status
Partnered for First-in-Human Trial
Company
Gb Sciences

About Gb Sciences

Gb Sciences is a Las Vegas-based biopharmaceutical company founded in 2009 with a mission to bridge botanical medicine and modern drug discovery. Its core strategy utilizes the AI-powered PhAROS platform to deconvolute plant mixtures into defined, synergistic drug candidates. The company's key achievement is a patented, cannabinoid-based Parkinson's disease therapy with positive animal proof-of-concept data, now partnered for first-in-human trial sponsorship, alongside a broader preclinical pipeline.

View full company profile

Therapeutic Areas

NeurologyInflammation/ImmunologyCardiology

Other Parkinson's Disease Drugs

DrugCompanyPhase
NPT200-11Neuropore TherapiesPhase 1
VXX-301VaxxinityPreclinical
BAN2802BioArcticPhase 1
CNM-Au8ClenePhase 2
hpSC-Derived Neural/Dopaminergic CellsInternational Stem CellPreclinical/Early Clinical
SLS-004Seelos TherapeuticsPreclinical
SLS-007Seelos TherapeuticsPreclinical
Parkinson's Disease ResearchProgenaBiomeResearch
A9 Dopaminergic Neuron TherapyTrailhead BiosystemsPre-clinical
golexanoloneUmecrine CognitionPreclinical
Bezisterim (NE3107)BioViePhase 2
Parkin Activator ProgramProgenraPre-clinical